Abstract
PEDF is an effective inhibitor of angiogenesis in the eye with neuronal differentiating activity. Here, we show that PEDF prevents the AGEs-elicited eNOS reduction through its anti-oxidative properties. Our present study suggests that PEDF may also play a protective role against atherosclerosis.
Keywords: AGEs, eNOS, oxidative stress, PEDF, peroxynitrite
Protein & Peptide Letters
Title: Pigment Epithelium-Derived Factor (PEDF) Prevents Advanced Glycation End Products (AGEs)-Elicited Endothelial Nitric Oxide Synthase (eNOS) Reduction Through Its Anti-Oxidative Properties
Volume: 14 Issue: 8
Author(s): Sho-ichi Yamagishi, Seiji Ueda, Takanori Matsui, Kazuo Nakamura, Tsutomu Imaizumi, Masayoshi Takeuchi and Seiya Okuda
Affiliation:
Keywords: AGEs, eNOS, oxidative stress, PEDF, peroxynitrite
Abstract: PEDF is an effective inhibitor of angiogenesis in the eye with neuronal differentiating activity. Here, we show that PEDF prevents the AGEs-elicited eNOS reduction through its anti-oxidative properties. Our present study suggests that PEDF may also play a protective role against atherosclerosis.
Export Options
About this article
Cite this article as:
Sho-ichi Yamagishi , Seiji Ueda , Takanori Matsui , Kazuo Nakamura , Tsutomu Imaizumi , Masayoshi Takeuchi and Seiya Okuda , Pigment Epithelium-Derived Factor (PEDF) Prevents Advanced Glycation End Products (AGEs)-Elicited Endothelial Nitric Oxide Synthase (eNOS) Reduction Through Its Anti-Oxidative Properties, Protein & Peptide Letters 2007; 14 (8) . https://dx.doi.org/10.2174/092986607781483705
DOI https://dx.doi.org/10.2174/092986607781483705 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Chaperonopathies and Chaperonotherapy. Hsp60 as Therapeutic Target in Cancer: Potential Benefits and Risks
Current Pharmaceutical Design Inherited Renal Diseases
Current Pediatric Reviews Recent Updates on Current and Upcoming Biomarkers for Cardiovascular Diseases
Current Pharmaceutical Design An Association between MicroRNA-21 Expression and Vitamin D Deficiency in Coronary Artery Disease
MicroRNA Patent Selections
Recent Patents on DNA & Gene Sequences Targeted Renal Delivery of Protein Kinase Inhibitors for the Treatment of Chronic Kidney Disease
Current Signal Transduction Therapy Vascular Abnormalities in Essential Hypertension
Current Pharmaceutical Design Combined Antiplatelet Therapy: Still a Sweeping Combination in Cardiology
Cardiovascular & Hematological Agents in Medicinal Chemistry Arterial Stiffness, Cognitive Dysfunction and Adherence to Antihypertensive Agents. Is there a Link to Hypertensive Patients?
Current Vascular Pharmacology Endoplasmic Reticulum Stress and Atherosclerosis
Current Hypertension Reviews Emerging Targets for the Treatment of Dyslipidemia
Current Medicinal Chemistry Pregnancy in Type 2 Diabetes Mellitus - Problems & Promises
Current Diabetes Reviews Vitamin D Metabolism and Potential Effects of Vitamin D Receptor Modulation in Chronic Kidney Disease
Current Drug Metabolism Vorapaxar, a Protease-Activated Receptor-1 Antagonist, a Double –Edged Sword!
Recent Advances in Cardiovascular Drug Discovery (Discontinued) Ezetimibe and Vascular Inflammation
Current Vascular Pharmacology Editorial [Hot Topic: Drugs Targeting Atherosclerosis: Current and Emerging Approaches (Executive Editors: Vangelis G. Manolopoulos and Anna Tavridou)]
Current Pharmaceutical Design Exogenous Heparin-Derivative Affords Protection Against Lipid Anomalies and Apoptotic DNA Damage in Experimental Atherogenesis
Vascular Disease Prevention (Discontinued) Diabetic Cognitive Dysfunction: From Bench to Clinic
Current Medicinal Chemistry Cyclooxygenase-2 Inhibitors: A Painful Lesson
Cardiovascular & Hematological Disorders-Drug Targets Vascular Endothelial Primary Cilia: Mechanosensation and Hypertension
Current Hypertension Reviews